Immune Checkpoint Inhibitors in the Treatment of Stage III NSCLC: A Primer for Managed Care Pharmacy

Watch this CPE-certified Webcast of a CCO symposium at AMCP 2018, where Mark M. Awad, MD, PhD; Sandra Cuellar, PharmD, BCOP; and Ali McBride, PharmD, MS, BCOP, FAzPA, review and discuss the latest data on immune checkpoint inhibitors for stage III NSCLC as they apply to pharmacists and managed care professionals.
Mark M. Awad, MD, PhD
Sandra Cuellar, PharmD, BCOP
Ali McBride, PharmD, MS, BCOP, FAzPA
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: June 12, 2018 Expiration: June 11, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review evidence-based strategies for the management of stage III NSCLC, considering systemic and local therapeutic modalities
  • Discuss the biologic rationale for using immune checkpoint inhibitors in early-stage cancers
  • Develop management strategies to address immune-mediated adverse events in patients receiving checkpoint inhibitors
  • Educate patients about the benefits and risks of using immune checkpoint inhibitor therapy and provide preventive strategies to reduce or ameliorate these toxicities
  • Explain the role of the oncology pharmacist in optimizing the use of checkpoint inhibitor therapy for unresectable stage III NSCLC and opportunities to advance oncology pharmacy services
  • Address challenging questions regarding the management of unresectable stage III NSCLC and discuss ways the managed care pharmacist can aid in the implementation of clinical pathways to deliver quality care

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Mark M. Awad, MD, PhD

Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Mark M. Awad, MD, PhD, has no real or apparent conflicts of interest to report.
Sandra Cuellar, PharmD, BCOP

Clinical Assistant Professor
Clinical Oncology Pharmacist
Department of Pharmacy Practice
University of Illinois Hospital & Health Sciences System
Chicago, Illinois

Sandra Cuellar, PharmD, BCOP, has disclosed that she has received consulting fees from Eisai and fees for non-CME/CE services from Genentech.
Ali McBride, PharmD, MS, BCOP, FAzPA

Clinical Coordinator
Department of Pharmacy
The University of Arizona Cancer Center
Tucson, Arizona

Ali McBride, PharmD, MS, BCOP, FAzPA, has disclosed that he has served as a speaker for AstraZeneca.

Staff

Rachael M. Andrie, PhD

Associate Managing Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with non-small-cell lung cancer.

Goal

The goal of this activity is to educate pharmacists and managed care professionals about advances in the clinical management of patients with stage III non-small-cell lung cancer.

Pharmacist Continuing Education

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008162-9999-18-165-H01-P

Type of Activity: Application

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 12, 2018, through June 11, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

How to use dual HER2-targeted adjuvant therapy with trastuzumab and pertuzumab and extended therapy with neratinib for patients with HER2+ EBC

person default Madelaine Kuiper, NP Registered Nurses: 1.0 Nursing contact hour Released: November 13, 2018 Expiration: November 12, 2019

Downloadable slides with expert advice for managing patients with non-small-cell lung cancer (NSCLC) using the latest treatment strategies.

Jonathan Dowell, MD
Program Director
Melissa L. Johnson, MD
Program Director
Released: November 13, 2018

Expert slideset reviewing how to optimize ALL treatment and manage CRS and neurologic adverse events with BiTE constructs and CAR T-cell therapies.

Amir Fathi, MD Released: November 12, 2018

Immunotherapies in B-cell ALL: Get up to date on how BiTE constructs and CAR T-cells are improving response rates in this challenging malignancy.

Amir Fathi, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: November 12, 2018 Expiration: November 11, 2019
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?